Brief: Soligenix Achieves Enrollment Milestone For Planned Interim Analysis In Confirmatory Phase 3 Clinical Trial Of HyBryte For Treatment Of Cutaneous T-Cell Lymphoma
19/11/2025 13:39
Nov 19 (Reuters) - Soligenix Inc SNGX.O: SOLIGENIX ACHIEVES ENROLLMENT MILESTONE FOR PLANNED INTERIM ANALYSIS IN CONFIRMATORY PHASE 3 CLINICAL TRIAL OF HYBRYTE™ FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA Source text: ID:nPn1d2Z6la Further company coverage: SNGX.O ((Reuters.Briefs@thomsonreuters.com;))